Stocks Health care LBRX
NASDAQ · Health careLB Pharmaceuticals Inc (LBRX)
It posted a net loss of $85.7M. In fiscal 2025 capital spending exceeded operating cash flow by $35.3M. At June 30, 2026 it held $283.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
What LB Pharmaceuticals Inc does
LB Pharmaceuticals Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LBRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$25.2M | -$3.13 | -$35.3M |
| 2025 | n/a | -$63.1M | -$176.15 | -$53.8M |
Latest SEC filings
What LB Pharmaceuticals Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 15, 2026
- September 15, 2026
- September 3, 2026
- September 3, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026
- August 11, 2026
- July 29, 2026Passive stake changed SCHEDULE 13G/A
- July 29, 2026
Questions about LBRX
What does LB Pharmaceuticals Inc do?
LB Pharmaceuticals Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LBRX.
Is LB Pharmaceuticals Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $85.7M.
When did LB Pharmaceuticals Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the new insider holdings from September 24, 2026.
Similar companies
Follow LBRX
Get an email when LB Pharmaceuticals Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow LBRX: get an email when it filesWhere the numbers come from
Financial figures are the values LB Pharmaceuticals Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.